Results 31 to 40 of about 53,515 (238)

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

open access: yesClinical and Translational Science, 2023
This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC).
Bruno Sangro   +9 more
doaj   +1 more source

Ipilimumab [PDF]

open access: yesDrugs in R&D, 2010
Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in phase III development for the melanoma and prostate cancer indications, and phase II ...
openaire   +2 more sources

The price of tumor control [PDF]

open access: yes, 2013
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Berking, Carola   +35 more
core   +1 more source

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer

open access: yesFrontiers in Pharmacology, 2021
Purpose: The effectiveness of nivolumab plus ipilimumab for advanced non-small cell lung cancer (NSCLC) has been demonstrated. Decisions have to be made about allocating healthcare resources.
Xuezhi Hao, Aizong Shen, Bin Wu
doaj   +1 more source

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

open access: yesBMC Cancer, 2020
Background For novel cancer treatments, effectiveness in clinical practice is not always aligned with clinical efficacy results. As such it is important to understand a treatment’s real-world effectiveness.
Wei Fang Dai   +10 more
doaj   +1 more source

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization

open access: yesCancer Medicine, 2023
Background The efficacy‐effectiveness gap between randomized trial and real‐world evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has been well characterized by previous literature, consistent with initial concerns ...
Brandon Lu   +12 more
doaj   +1 more source

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

open access: yes, 2023
lumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IVmelanoma,with benefit sustained at 4 years.
Gogas, Helen   +7 more
core   +1 more source

Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma

open access: yesCase Reports in Endocrinology, 2016
Objective. Thyroid disease has been reported among the endocrinopathies that can occur after treatment with ipilimumab. Graves’ disease, however, has been rarely reported with this medication.
Umal Azmat   +4 more
doaj   +1 more source

Acute visual loss after ipilimumab treatment for metastatic melanoma

open access: yesJournal for ImmunoTherapy of Cancer, 2016
Background Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs).Case ...
Melissa A. Wilson   +8 more
doaj   +1 more source

Treating metastatic melanoma with ipilimumab: Clinical activity, health-related quality of life, and combination with a telomerase peptide vaccine

open access: yes, 2022
Ipilimumab was the first therapy with evidenced survival benefits in patients with metastatic melanoma. Based on two clinical trials, the thesis aimed to assess the efficacy, toxicity and health-related quality of life in a real-world population with ...
Aamdal, Elin
core   +1 more source

Home - About - Disclaimer - Privacy